Aparna Raj Parikh: 1st Steering Committee Meeting of Our “RER” Team
Aparna Raj Parikh, Associate Professor of Medicine at Harvard Medical School and a Gastrointestinal Oncologist at Massachusetts General Hospital, reshared a post by FDA Oncology on X, adding:
“1st steering committee meeting of our “RER” (Reversing early recurrences) team last week in Cambridge.
This group is bringing together cancer centers, pharma, patients, advocacy groups & regulators drive innovation in ctDNA/MRD.
Look forward to diving into new U.S. FDA guidance.”
Quoting FDA Oncology‘s post:
“FDA issued final guidance, Use of Circulating Tumor DNA for Curative Intent Solid Tumor Drug Development, to help sponsors using ctDNA as a biomarker in trials under an IND or to support approval of products for treating early-stage solid tumors.”
Dr. Aparna Raj Parikh is an Associate Professor of Medicine at Harvard Medical School and a Gastrointestinal Oncologist at Massachusetts General Hospital, where she has been practicing since September 2016. She is affiliated with the Tucker Gosnell Center for Gastrointestinal Cancers and the Henri and Belinda Termeer Center for Targeted Therapies. Dr. Parikh’s clinical interests include clinical trials, clinical research, gastrointestinal cancer, global health, immunotherapy, and Phase I clinical trials.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023